Current mainstream pharmacotherapy of glaucoma is the delivery of intraocular pressure-lowering medication via topical instillation. But, this dosage form has practical limitations due to well-known ocular barriers to drug transport. For the first time, highly efficient compound eye drop formulation is designed based on the idea of innovative glutathione-functionalized gelling materials. Our biomaterials-based ophthalmic drops can better improve drug bioavailabilityantiglaucoma efficacy than currently marketed eye drops, thereby showing future clinical translational potential.

To overcome the well-recognized drawbacks of using ophthalmic drops for glaucoma treatment, a highly efficient compound eye drop formulation is developed based on the idea of innovative biomaterials. Due to its excellent mucoadhesivetunable cell-junction capabilities, antioxidant glutathione-functionalized gelling system can better improve drug bioavailabilityantiglaucoma efficacy than currently marketed eye drops, thereby showing future clinical translational potential for new dosage form design of antiglaucoma medications.

Herein, a highly efficient compound eye drop formulation based on the idea of innovative biomaterial design has excellent mucoadhesivetunable cell-junction capabilities as well as strong antioxidative properties. Therefore, glutathione-functionalized gelling system facilitates the development of a more promising pharmaceutic formulation (as compared to currently marketed eye drop) for the treatment of glaucomaother external/internal ocular diseases. Our biomaterial-based delivery platform may also hold future potential for nucleic acidcellular therapeutics.

天使投資人、策略合作夥伴